University of Utah Researchers Launched Alzheimer's Venture

Dr. Donna Cross founded Caelium to advance a potential brain treatment derived from a common cancer drug.

Updated on Sept. 28, 2026 in Alzheimer’s

Glass laboratory beakers with clear liquid solution on a sterile white surface, representing pharmaceutical research. — University of Utah researchers have launched Caelium, a new venture dedicated to developing a potential Alzheimer's treatment using the repurposed cancer drug Paclitaxel. AI Illustration. Upload story photo >

Live Poll

Do you think private donations should play a larger role in funding early-stage medical research?

University of Utah researcher Dr. Donna Cross and Satoshi Minoshima have launched Caelium to develop a potential Alzheimer's treatment. The startup aims to mass-produce the cancer drug Paclitaxel, which has demonstrated success in reversing brain injury in mice.

Why it matters

The venture seeks to apply this research to treat neurodegenerative conditions including Alzheimer's, MS, ALS, and Parkinson's. Researchers believe the drug could strengthen the brain against disease, injury, and environmental damage.

A private donor contributed $450,000 to the project, supplemented by a $20,000 personal investment from Dr. Cross. Clinical trials are projected to cost between $5 million and $10 million.

The players

Dr. Donna Cross

She is a neuroscientific researcher at the University of Utah who is leading the effort to treat brain diseases.

Satoshi Minoshima

He is a co-founder of Caelium who is working alongside Dr. Cross to bring the drug to clinical production.

Caelium

This startup organization was formed to research mass-production methods and secure funding for medical trials.

The details

Caelium focuses on the drug Paclitaxel, which previously showed the ability to reverse brain injury in mice trials concluded two years ago. The team is currently researching mass-production methods while seeking necessary pharmaceutical funding to proceed to human testing.

17 years ago an administrator was diagnosed with breast cancer and MS.
2 years ago mouse trials for the drug were concluded.
Clinical trials could be completed in under 2 years.
The drug could be publicly available within 5 years.

Health Landscape

This venture builds upon the University of Utah neuroscientific research initiatives to translate laboratory findings into viable medical treatments. It marks a significant transition from academic discovery to the competitive, high-risk commercial pharmaceutical sector.

The development could eventually provide a new treatment option for patients suffering from neurodegenerative conditions. However, the path to availability depends on securing significant capital for clinical trials and successfully navigating federal regulatory standards.

The takeaway

Translating promising mouse-model data into human clinical trials requires substantial funding and time. Prospective patients and families should remain cautious as the treatment remains in the early stages of corporate development.